MTOR and hepatocellular carcinoma: Levels of glycolysis (i.e., hexokinase II), de novo lipogenesis (i.e., fatty acid synthase, FASN) and the AKT/mTOR pathway (i.e., pAKT, pRPS6), were significantly lower in KO-HCC in comparison to WT-HCC.